We try to create processes in the office to help prevent common bottlenecks that affect access to care for our patients. The one pattern that I can’t seem to mitigate is the fear of vaginal estrogen.
What do all of these cases have in common? Therapeutic success, patient satisfaction and drugs being used off-label for treating conditions they have no official indication for.
May 30 is World MS Day. I’d like to take the opportunity to discuss the importance of pharmacogenomics in providing complete care for patients with multiple sclerosis.